Back to top
more

CVS Health (CVS)

(Delayed Data from NYSE)

$62.47 USD

62.47
11,378,135

+0.37 (0.60%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $62.49 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.

Shaun Pruitt headshot

3 Medical Stocks to Consider as Markets Take a Breather

by Shaun Pruitt

These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.

Mark Vickery headshot

Economy Heating Up on PCE for June

by Mark Vickery

Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.

Zacks Equity Research

PCE Comes in Warmer Than Expected

by Zacks Equity Research

PCE Comes in Warmer Than Expected.

Zacks Equity Research

CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised

by Zacks Equity Research

CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.

Zacks Equity Research

CVS Health (CVS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

CVS Health (CVS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

CVS Health (CVS) delivered earnings and revenue surprises of +23.13% and +5.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.

Moumi Mondal headshot

CVS Health Care Delivery: Will the Growth Momentum Last in Q2?

by Moumi Mondal

CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.

Zacks Equity Research

Will Exome and Genome Growth Boost WGS' Q2 Earnings?

by Zacks Equity Research

GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.

Urmimala Biswas headshot

CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?

by Urmimala Biswas

CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.

Zacks Equity Research

BrightSpring Health Services, Inc. (BTSG) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BrightSpring Health Services, Inc. (BTSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why CVS Health (CVS) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the most recent trading session, CVS Health (CVS) closed at $58.75, indicating a -5.01% shift from the previous trading day.

Zacks Equity Research

CVS or DHR: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CVS vs. DHR: Which Stock Is the Better Value Option?

Zacks Equity Research

Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?

by Zacks Equity Research

ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.

Zacks Equity Research

CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Urmimala Biswas headshot

CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?

by Urmimala Biswas

Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moumi Mondal headshot

What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?

by Moumi Mondal

CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.

Zacks Equity Research

Zacks.com featured highlights CVS Health, Signet Jewelers, KB Financial, Affiliated Managers and PagSeguro Digital

by Zacks Equity Research

CVS, SIG, KB, AMG, and PAGS boast strong EPS growth projections and trade at attractive price-to-book ratios.

Zacks Equity Research

Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks

by Zacks Equity Research

CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Kinjel Shah headshot

5 Low Price-to-Book Stocks That Should Be in Your Portfolio Now

by Kinjel Shah

Low P/B stocks like CVS, SIG, KB, AMG and PAGS are flashing value signals with strong EPS growth projections and solid fundamentals.

Zacks Equity Research

Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings

by Zacks Equity Research

EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.

Zacks Equity Research

Labcorp Q2 Earnings Preview: Diagnostics Strength in Focus

by Zacks Equity Research

LH is likely to report Q2 growth with diagnostics momentum, key acquisitions, and new biomarker tests bolstering revenue gains.